Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories

Yannick Hoyos-Mallecot, Thierry Naas, Rémy A. Bonnin, Rafael Patino, Philippe Glaser, Nicolas Fortineau, Laurent Dortet
Yannick Hoyos-Mallecot
aBacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
bEA7361, Université Paris Sud, Université Paris Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
cAssociated French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Naas
aBacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
bEA7361, Université Paris Sud, Université Paris Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
cAssociated French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France
dEvolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-Assistance Publique-Hôpitaux de Paris-Université Paris Sud, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thierry Naas
Rémy A. Bonnin
aBacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
bEA7361, Université Paris Sud, Université Paris Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
cAssociated French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France
dEvolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-Assistance Publique-Hôpitaux de Paris-Université Paris Sud, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Patino
dEvolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-Assistance Publique-Hôpitaux de Paris-Université Paris Sud, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Glaser
dEvolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-Assistance Publique-Hôpitaux de Paris-Université Paris Sud, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philippe Glaser
Nicolas Fortineau
aBacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
bEA7361, Université Paris Sud, Université Paris Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
cAssociated French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France
dEvolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-Assistance Publique-Hôpitaux de Paris-Université Paris Sud, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Dortet
aBacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
bEA7361, Université Paris Sud, Université Paris Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
cAssociated French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France
dEvolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-Assistance Publique-Hôpitaux de Paris-Université Paris Sud, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00818-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

OXA-244 is a single-point-mutant derivative of OXA-48 displaying reduced carbapenemase activity. Here, we report the microbiological features of seven OXA-244-producing Escherichia coli isolates. Only one isolate grew on ChromID Carba Smart medium (bioMérieux), but six of the seven isolates grew on ChromID extended-spectrum-β-lactamase (ESBL) medium (bioMérieux), as they coproduced an ESBL and/or a plasmid-encoded cephalosporinase. The production of a carbapenemase was detected in 57.1%, 71.4%, 71.4%, and 100% of the E. coli isolates using the Carba NP test, the Rapidec Carba NP test (bioMérieux), a matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) hydrolysis assay (Bruker), and the OXA-48 K-SeT assay (Coris BioConcept), respectively. Our results indicate that OXA-244-producing E. coli isolates are difficult to detect, which may lead to their silent spread.

TEXT

The emergence of carbapenemase-producing Enterobacteriaceae (CPE) is becoming a major clinical issue (1). In this context, expert committees have set up guidelines to prevent the spread of CPEs (2). Thus, it is recommended to screen individuals at risk of being colonized, especially patients who were hospitalized previously in countries with high CPE prevalence, in order to isolate colonized patients as soon as possible, to implement contact precautions, and to strongly recommend cohorting with dedicated nursing staff. Screening procedures involving plating of rectal swabs on screening medium to detect all carbapenem-resistant isolates, with high sensitivity and sufficient specificity to rule out CPE carriage, should be performed as soon as possible (2, 3).

OXA-244, a single-point-mutant derivative of OXA-48 with reduced carbapenemase activity, was initially observed in a Spanish Klebsiella pneumoniae isolate (4). Subsequently, it was fortuitously found in a CTX-M-producing Escherichia coli isolate in Germany (5), in four Enterobacter aerogenes isolates in Russia (6), in E. coli VAL from France (7), and in an E. coli isolate from Southeast Asia that coproduced CTX-M-14 (8). While the blaOXA-244 gene was chromosomally encoded in the E. coli VAL isolate, it was plasmid located in K. pneumoniae and E. aerogenes (4, 6, 7).

The aim of this study was to evaluate different screening approaches and confirmatory tests useful for detecting OXA-244-producing E. coli (OXA-244-Ec) isolates. In addition, we investigated the genetic relatedness of seven OXA-244-Ec isolates from different geographical origins that were received at the French National Reference Center (F-NRC) for CPEs.

In August 2015, a 44-year-old Egyptian man was admitted to the Bicêtre Hospital (Le Kremlin-Bicêtre, France) for an episode of erysipelas of his right leg, which was treated with intravenous amoxicillin. After 2 weeks, the patient was discharged with a favorable outcome. Because this patient (as a repatriated patient) was considered to be at risk for multidrug-resistant (MDR) bacterial carriage according to French CPE guidelines, rectal swabs were plated on ChromID Carba Smart medium (bioMérieux, La Balme-les-Grottes, France), a selective chromogenic biplate for screening for CPE, and ChromID ESBL medium (bioMérieux), a chromogenic plate for screening for extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae. The ChromID Carba Smart medium remained sterile, while E. coli 85H4 grew on the ChromID ESBL plate (Table 1). Antimicrobial susceptibilities, as determined by the disk diffusion technique on Mueller-Hinton agar (Bio-Rad, Marnes-La-Coquette, France) and interpreted according to the EUCAST breakpoints, as updated in 2016 (http://www.eucast.org/clinical_breakpoints/ ), revealed that the E. coli 85H4 isolate was highly resistant to temocillin (absence of an inhibition zone) and displayed reduced susceptibility to ertapenem (zone diameter of 19 mm), thus requiring confirmatory testing for carbapenemase production, as recommended by EUCAST (9). The results of the Rapidec Carba NP test (bioMérieux) were positive for E. coli 85H4, although no colony grew on the ChromID Carba Smart plate (10). In-house PCR sequencing, as described previously (11), revealed the presence of a gene coding for OXA-244, a R214G OXA-48 variant (Table 1) (4). Since OXA-244-Ec 85H4 also produced an ESBL, the ChromID ESBL medium was used to screen 34 contact patients for the Egyptian patient; for 4 patients, positive E. coli cultures on ChromID ESBL medium were obtained. Antibiotic susceptibility testing and in-house PCR testing of five independent colonies revealed that none carried the blaOXA-244 gene (data not shown).

View this table:
  • View inline
  • View popup
TABLE 1

Clinical and phenotypic characteristics of the OXA-244-Ec isolates

Phenotypic characterization of OXA-244-Ec.The ability to reliably detect OXA-244-Ec using ChromID Carba Smart and ChromID ESBL plates and to confirm the presence of a carbapenemase was further investigated with E. coli VAL (7) and five other OXA-244-Ec isolates referred to the F-NRC for CPEs. The susceptibilities to different antibiotics of the seven OXA-244-Ec isolates are shown in Table 2. For all OXA-244-Ec isolates, 100 μl of a 0.5 McFarland solution was plated on ChromID ESBL and ChromID Carba Smart media. Only one of the seven isolates did not grow on the ChromID ESBL medium (Table 1); that isolate was susceptible to cephalosporins, which explained the absence of growth on the ChromID ESBL medium (Table 2). In contrast, only one isolate grew on the OXA-48 side of the ChromID Carba Smart plate (Table 1) and none grew on the Carba side; that strain displayed the highest MICs for temocillin (>1,024 mg/liter) and for moxalactam, a β-lactam classically used for testing impermeability problems (Table 1) (12). All of the OXA-244-Ec isolates exhibited only slightly decreased susceptibility to carbapenems, which explained the absence of growth on the Carba side of the ChromID Carba Smart plate (Table 1). The biochemical confirmation tests used for carbapenemase detection were positive for 57.1% (4/7 isolates), 71.4% (5/7 isolates), 71.4% (5/7 isolates), and 100% (7/7 isolates) of the isolates using the Carba NP test (13), the Rapidec Carba NP test (bioMérieux) (10), the MBT STAR-BL test, a commercial matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS)-based assay (Maldi-Biotyper; Bruker, Illkirch, France), and a lateral flow immunoassay (LFIA) called the OXA-48 K-SeT assay (Coris BioConcept, Gembloux, Belgium) (14) respectively (Table 1).

View this table:
  • View inline
  • View popup
TABLE 2

Resistance genes and phenotypic susceptibility of the OXA-244-Ec isolates

Molecular detection of resistance genes.Using the commercially available Xpert Carba-R v2 assay, as recommended by the manufacturer (Cepheid, Toulouse, France) (15, 16), blaOXA-48-like genes were detected in all seven OXA-244-Ec isolates. Whole-genome sequencing (WGS) was performed to determine the resistome of these OXA-244-Ec isolates using the ResFinder server (http://cge.cbs.dtu.dk/services/ResFinder-2.1 ) (17) (Table 2). A good correlation between the genetic profile and the phenotypic resistance profile for routinely tested β-lactams, colistin, fosfomycin, phenicol, sulfonamide-trimethoprim, and tetracycline antibiotics was found (Table 2). For aminoglycosides, only netilmicin, amikacin, tobramycin, and gentamicin were tested. However, different aminoglycoside resistance genes (e.g., aph3-1a, aph3-1b, aph6-1d, and aadA1), which confer resistance to other aminoglycosides that were not tested because they were not clinically relevant, were found in some of the isolates. Of note, isolate OXA-244-Ec 86J1 was resistant to fluoroquinolones due to substitutions in the quinolone resistance determinant region, as revealed by analysis with the RAST server (rast.nmpdr.org) (18) and comparison with that of K. pneumoniae ATCC 13883 (GenBank accession no. DQ673325 ), i.e., in codons 83 (Ser83-Leu) and 87 (Asp87-Asn) for GyrA and in codons 80 (Ser80-Ile) and 84 (Glu84-Gly) for ParC, which are known to confer fluoroquinolone resistance.

Among the seven isolates, only E. coli VAL had no other β-lactam resistance gene besides the blaOXA-244 gene; consequently, that strain was susceptible to cephalosporins (7). For the remaining six isolates, an ESBL gene (blaCTX-M-14 or blaCTX-M-27) or a plasmid-encoded cephalosporinase gene (blaCMY-42 or blaCMY-2) was always associated with the blaOXA-244 gene (Table 2).

Genetic relatedness of OXA-244-Ec isolates.The seven OXA-244-Ec isolates corresponded to four different clones, as revealed by repetitive element sequence-based PCR (rep-PCR) using the DiversiLab system (bioMérieux), following the manufacturer's recommendations. Two distinct clones were identified among the Egyptian isolates (Fig. 1 and Table 1). Multilocus sequence typing (MLST) results deduced from WGS data using the MLST 1.8 server (https://cge.cbs.dtu.dk/services/MLST ) (19) confirmed the rep-PCR results, as each rep-PCR pattern corresponded to a different sequence type (ST), i.e., ST-38, ST-361, ST-1722, or ST-3541 (Table 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Rep-PCR analysis using the DiversiLab technique, showing a dendrogram and computer-generated image of rep-PCR banding patterns of OXA-244-Ec isolates and an E. coli isolate of an unrelated strain. As recommended by the manufacturer, a cutoff value of 95% similarity defined a cluster.

Genetic environment and support of blaOXA-244 genes.For three strains (78B5, 62D3, and 69E6), no plasmids could be detected after electrophoresis of Kieser-extracted DNA (11) (see Fig. S1 in the supplemental material). Electroporation of the extracted plasmids, as described previously (11), yielded E. coli TOP10 transformants for only three strains (86J1, 85H4, and 73G4). However, only ESBL/plasmid-encoded blaAMP-C genes were found in those transformants. Thus, all of these findings suggest a chromosomal location for the blaOXA-244 gene. PCR mapping of the blaOXA-244 gene flanking sequences showed that all were bracketed by two IS1R copies, forming an IS1R-made composite transposon named Tn51098 (Fig. S2A). In all isolates, although they belonged to different rep-PCR patterns or STs, Tn51098 was inserted into a gene encoding an intrinsic endonuclease from E. coli, as described previously (7) (Fig. S2B). Dissemination of E. coli isolates harboring a chromosomally located blaOXA-48-like gene has recently been linked to one ST, namely, ST38 (20, 21). In our study, however, four different STs that have integrated the blaOXA-244 carbapenemase gene into the chromosome were found, indicating that diffusion could be more related to the mobility of blaOXA-244-carrying IS1R-made composite transposons (Tn51098) than to clonal expansion.

Conclusions.Detection of CPEs remains a challenge for clinical microbiology laboratories (22), especially with OXA-244-Ec isolates, since they do not grow on ChromID Carba Smart plates, one of the most used types of medium for the screening of CPEs (7, 23–25). However, as most OXA-244-Ec isolates also produced an ESBL, they could grow on ChromID ESBL medium. In the absence of expanded-spectrum hydrolyzing enzymes (such as in E. coli VAL), detection of OXA-244-Ec strains would rely only on molecular tests directly with rectal swabs (15) and on LFIA tests, such as OXA-48 K-SeT, with cultured bacteria (14). In France, OXA-244-Ec strains are still rare, i.e., 0%, 0.3% (two isolates), 0.2% (two isolates), 0.6% (six isolates), and 0.7% (eight isolates) of all OXA-48-like enzymes in 2012, 2013, 2014, 2015, and 2016, respectively, but whether this indicates a real low prevalence or is the result of underdetection is not known.

Accession number(s).The E. coli genome sequences of isolates 86J1, 62D3, 69E6, 78B5, 35J9, 73G4, and 85H4, used in this study, were deposited in GenBank under the accession numbers MKGU00000000 , MKGY00000000 , MKGZ00000000 , MKGT00000000 , MKGX00000000 , MKGV00000000 , and MKGW00000000 , respectively.

ACKNOWLEDGMENTS

This work was funded by grants from Assistance Publique-Hôpitaux de Paris, Santé Publique France, and the French Ministry of Education and Research through the Université Paris Sud. T.N., N.F., and L.D. are members of the Laboratory of Excellence Lermit, supported by a grant from the Agence Nationale pour la Recherche (grant ANR-10-LABX-33).

L.D. holds an international patent for the Carba NP test that was filed on behalf of INSERM Transfert and subsequently licensed to bioMérieux.

FOOTNOTES

    • Received 21 April 2017.
    • Returned for modification 25 May 2017.
    • Accepted 29 June 2017.
    • Accepted manuscript posted online 3 July 2017.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.00818-17 .

  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Doi Y,
    2. Paterson DL
    . 2015. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med36:74–84. doi:10.1055/s-0035-1544208.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Grundmann H,
    2. Livermore DM,
    3. Giske CG,
    4. Canton R,
    5. Rossolini GM,
    6. Campos J,
    7. Vatopoulos A,
    8. Gniadkowski M,
    9. Toth A,
    10. Pfeifer Y,
    11. Jarlier V,
    12. Carmeli Y
    . 2010. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill15(46):pii=19711. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19711.
    OpenUrlCrossRef
  3. 3.↵
    1. Viau R,
    2. Frank KM,
    3. Jacobs MR,
    4. Wilson B,
    5. Kaye K,
    6. Donskey CJ,
    7. Perez F,
    8. Endimiani A,
    9. Bonomo RA
    . 2016. Intestinal carriage of carbapenemase-producing organisms: current status of surveillance. Methods Clin Microbiol Rev29:1–27. doi:10.1128/CMR.00108-14.
    OpenUrlCrossRef
  4. 4.↵
    1. Oteo J,
    2. Hernández JM,
    3. Espasa M,
    4. Fleites A,
    5. Sáez D,
    6. Bautista V,
    7. Pérez-Vázquez M,
    8. Fernández-García MD,
    9. Delgado-Iribarren A,
    10. Sánchez-Romero I,
    11. García-Picazo L,
    12. Miguel MD,
    13. Solís S,
    14. Aznar E,
    15. Trujillo G,
    16. Mediavilla C,
    17. Fontanals D,
    18. Rojo S,
    19. Vindel A,
    20. Campos J
    . 2013. Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain. J Antimicrob Chemother68:317–321. doi:10.1093/jac/dks383.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Valenza G,
    2. Nickel S,
    3. Pfeifer Y,
    4. Eller C,
    5. Krupa E,
    6. Lehner-Reindl V,
    7. Höller C
    . 2014. Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother58:1228–1230. doi:10.1128/AAC.01993-13.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Fursova NK,
    2. Astashkin EI,
    3. Knyazeva AI,
    4. Kartsev NN,
    5. Leonova ES,
    6. Ershova ON,
    7. Alexandrova IA,
    8. Kurdyumova NV,
    9. Sazikina SY,
    10. Volozhantsev NV,
    11. Svetoch EA,
    12. Dyatlov IA
    . 2015. The spread of blaOXA-48 and blaOXA-244 carbapenemase genes among Klebsiella pneumoniae, Proteus mirabilis and Enterobacter spp. isolated in Moscow, Russia. Ann Clin Microbiol Antimicrob14:46. doi:10.1186/s12941-015-0108-y.
    OpenUrlCrossRef
  7. 7.↵
    1. Potron A,
    2. Poirel L,
    3. Dortet L,
    4. Nordmann P
    . 2016. Characterisation of OXA-244, a chromosomally-encoded OXA-48-like β-lactamase from Escherichia coli. Int J Antimicrob Agents47:102–103. doi:10.1016/j.ijantimicag.2015.10.015.
    OpenUrlCrossRef
  8. 8.↵
    1. van Hattem JM,
    2. Arcilla MS,
    3. Bootsma MC,
    4. van Genderen PJ,
    5. Goorhuis A,
    6. Grobusch MP,
    7. Molhoek N,
    8. Oude Lashof AM,
    9. Schultsz C,
    10. Stobberingh EE,
    11. Verbrugh HA,
    12. de Jong MD,
    13. Melles DC,
    14. Penders J
    . 2016. Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers. Future Microbiol11:857–864. doi:10.2217/fmb.16.18.
    OpenUrlCrossRef
  9. 9.↵
    1. Giske CG,
    2. Martinez-Martinez L,
    3. Cantón R,
    4. Stefani S,
    5. Skov R,
    6. Glupczynski Y,
    7. Nordmann P,
    8. Wootton M,
    9. Miriagou V,
    10. Simonsen GS,
    11. Zemlickova H,
    12. Cohen-Stuart J,
    13. Gniadkowski M
    . 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. EUCAST, Basel, Switzerland. http://www.eucast.org/resistance_mechanisms/.
  10. 10.↵
    1. Dortet L,
    2. Agathine A,
    3. Naas T,
    4. Cuzon G,
    5. Poirel L,
    6. Nordmann P
    . 2015. Evaluation of the RAPIDEC® CARBA NP, the Rapid CARB Screen® and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother70:3014–3022. doi:10.1093/jac/dkv213.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Cuzon G,
    2. Naas T,
    3. Truong H,
    4. Villegas M-V,
    5. Wisell KT,
    6. Carmeli Y,
    7. Gales AC,
    8. Navon-Venezia S,
    9. Quinn JP,
    10. Nordmann P
    . 2010. Worldwide diversity of Klebsiella pneumoniae that produce β-lactamase blaKPC-2. Gene Emerg Infect Dis16:1349–1356. doi:10.3201/eid1609.091389.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Komatsu Y,
    2. Murakami K,
    3. Nishikawa T
    . 1981. Penetration of moxalactam into its target proteins in Escherichia coli K-12: comparison of a highly moxalactam resistant mutant with its parent strain. Antimicrob Agents Chemother20:613–619. doi:10.1128/AAC.20.5.613.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Dortet L,
    2. Bréchard L,
    3. Poirel L,
    4. Nordmann P
    . 2014. Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test. J Med Microbiol63:772–776. doi:10.1099/jmm.0.071340-0.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Dortet L,
    2. Jousset A,
    3. Sainte-Rose V,
    4. Cuzon G,
    5. Naas T
    . 2016. Prospective evaluation of the OXA-48 K-SeT assay, an immunochromatographic test for the rapid detection of OXA-48-type carbapenemases. J Antimicrob Chemother71:1834–1840. doi:10.1093/jac/dkw058.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Dortet L,
    2. Fusaro M,
    3. Naas T
    . 2016. Improvement of the Xpert Carba-R kit for the detection of carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother60:3832–3837. doi:10.1128/AAC.00517-16.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Hoyos-Mallecot Y,
    2. Ouzani S,
    3. Dortet L,
    4. Fortineau N,
    5. Naas T
    . 2017. Performance of the Xpert® Carba-R v2 in the daily workflow of a hygiene unit in a country with a low prevalence of carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents49:774–777. doi:10.1016/j.ijantimicag.2017.01.025.
    OpenUrlCrossRef
  17. 17.↵
    1. Zankari E,
    2. Hasman H,
    3. Cosentino S,
    4. Vestergaard M,
    5. Rasmussen S,
    6. Lund O,
    7. Aarestrup FM,
    8. Larsen MV
    . 2012. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother67:2640–2644. doi:10.1093/jac/dks261.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Aziz RK,
    2. Bartels D,
    3. Best AA,
    4. DeJongh M,
    5. Disz T,
    6. Edwards RA,
    7. Formsma K,
    8. Gerdes S,
    9. Glass EM,
    10. Kubal M,
    11. Meyer F,
    12. Olsen GJ,
    13. Olson R,
    14. Osterman AL,
    15. Overbeek RA,
    16. McNeil LK,
    17. Paarmann D,
    18. Paczian T,
    19. Parrello B,
    20. Pusch GD,
    21. Reich C,
    22. Stevens R,
    23. Vassieva O,
    24. Vonstein V,
    25. Wilke A,
    26. Zagnitko O
    . 2008. The RAST server: rapid annotations using subsystems technology. BMC Genomics9:75. doi:10.1186/1471-2164-9-75.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Larsen MV,
    2. Cosentino S,
    3. Rasmussen S,
    4. Friis C,
    5. Hasman H,
    6. Marvig RL,
    7. Jelsbak L,
    8. Sicheritz-Pontén T,
    9. Ussery DW,
    10. Aarestrup FM,
    11. Lund O
    . 2012. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol50:1355–1361. doi:10.1128/JCM.06094-11.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Turton JF,
    2. Doumith M,
    3. Hopkins KL,
    4. Perry C,
    5. Meunier D,
    6. Woodford N
    . 2016. Clonal expansion of Escherichia coli ST38 carrying a chromosomally integrated OXA-48 carbapenemase gene. J Med Microbiol65:538–546. doi:10.1099/jmm.0.000248.
    OpenUrlCrossRef
  21. 21.↵
    1. Potron A,
    2. Poirel L,
    3. Rondinaud E,
    4. Nordmann P
    . 2013. Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill18(31):pii=20549. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20549.
    OpenUrlCrossRef
  22. 22.↵
    1. Hrabák J,
    2. Chudáčkova E,
    3. Papagiannitsis CC
    . 2014. Detection of carbapenemases in Enterobacteriaceae: a challenge for diagnostic microbiological laboratories. Clin Microbiol Infect20:839–853. doi:10.1111/1469-0691.12678.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Girlich D,
    2. Anglade C,
    3. Zambardi G,
    4. Nordmann P
    . 2013. Comparative evaluation of a novel chromogenic medium (chromID OXA-48) for detection of OXA-48 producing Enterobacteriaceae. Diagn Microbiol Infect Dis77:296–300. doi:10.1016/j.diagmicrobio.2013.08.015.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Oueslati S,
    2. Nordmann P,
    3. Poirel L
    . 2015. Heterogeneous hydrolytic features for OXA-48-like β-lactamases. J Antimicrob Chemother70:1059–1063.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Potron A,
    2. Rondinaud E,
    3. Poirel L,
    4. Belmonte O,
    5. Boyer S,
    6. Camiade S,
    7. Nordmann P
    . 2013. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from Enterobacteriaceae. Int J Antimicrob Agents41:325–329. doi:10.1016/j.ijantimicag.2012.11.007.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories
Yannick Hoyos-Mallecot, Thierry Naas, Rémy A. Bonnin, Rafael Patino, Philippe Glaser, Nicolas Fortineau, Laurent Dortet
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e00818-17; DOI: 10.1128/AAC.00818-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories
Yannick Hoyos-Mallecot, Thierry Naas, Rémy A. Bonnin, Rafael Patino, Philippe Glaser, Nicolas Fortineau, Laurent Dortet
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e00818-17; DOI: 10.1128/AAC.00818-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Escherichia coli
Escherichia coli Infections
beta-lactamases
OXA-244
detection
screening
tests
carbapenemase activity
OXA-48-like

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596